Key facts
- Dioseve’s last known valuation is $27.0M (Nov 2025).
- It has raised $20.8M; the latest was Early Stage VC ($4.0M) in Nov 2025.
- Notable investors include ANRI, Spiral Capital (Tokyo), DG Daiwa Ventures, WiL (World Innovation Lab), Coral Capital — 14 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 14 names
- ·Watchlist + deal alerts for Dioseve
- ·The full record, as it builds
Funding rounds
No funding rounds for Dioseve are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Dioseve
Developer of in vitro egg generation technology designed to create functional human oocytes. The company induces the differentiation of iPS cells into oocyte and ovarian somatic cells at high efficiency, enabling medical researchers and reproductive medicine professionals to advance infertility therapies, model reproductive aging, and investigate the mechanisms and genetic causes of reproductive disorders.
- Sector
- Healthcare
- HQ
- Tokyo, Japan
- Founded
- 2021
- Employees
- 6
- Website
- dioseve.com/
- Ownership
- Privately Held (backing)
Dioseve doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Dioseve shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Dioseve in its N-PORT filings yet. We sweep new filings monthly.